<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683564</url>
  </required_header>
  <id_info>
    <org_study_id>EPI-BOW015-003</org_study_id>
    <nct_id>NCT02683564</nct_id>
  </id_info>
  <brief_title>BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study</brief_title>
  <official_title>A Study of BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis on Stable Methotrexate: The UNIFORM Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epirus Biopharmaceuticals (Switzerland) GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epirus Biopharmaceuticals (Switzerland) GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blind, parallel group, multicentre global phase 3
      clinical study to evaluate the efficacy, safety and immunogenicity of BOW015
      (infliximab-EPIRUS) compared to Remicade in subjects with active Rheumatoid Arthritis (RA)
      despite Methotrexate (MTX) therapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>American College of Rheumatology (ACR) 20 clinical response</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR20</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diseases Activity Score (DAS)28 calculated with C-reactive protein (CRP)</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire-Disability Index (HAQ-DI)</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">548</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>BOW015</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infliximab-EPIRUS, 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remicade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remicade (infliximab) , 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOW015</intervention_name>
    <description>monoclonal antibody against TNF-alpha</description>
    <arm_group_label>BOW015</arm_group_label>
    <other_name>infliximab-EPIRUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remicade</intervention_name>
    <description>monoclonal antibody against TNF-alpha</description>
    <arm_group_label>Remicade</arm_group_label>
    <other_name>infliximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male and female, aged 18 to 80

          2. Diagnosis of Rheumatoid Arthritis (RA) according to the revised ACR/ EULAR 2010
             classification criteria for RA

          3. Patients must have ACR/EULAR 2010 classification criteria score â‰¥ 6

          4. Patients must have active disease

          5. Patients must have been on treatment with methotrexate

        Key Exclusion Criteria:

          1. Prior use of infliximab, adalimumab, certolizumab, golimumab, tocilizumab, rituximab,
             or etanercept or any other biological treatment

          2. Patients with any prior or current use of anakinra and abatacept

          3. Patients with suspected or confirmed current active tuberculosis (TB)

          4. Patients with latent tuberculosis must start treatment for latent tuberculosis

          5. Patients who have a current or past history of chronic infection with Hepatitis B,
             Hepatitis C, or infection with Human Immunodeficiency Virus-1 or-2

          6. History of completely excised and cured squamous carcinoma of the uterine cervix,
             cutaneous basal cell carcinoma or cutaneous squamous cell carcinoma

          7. History of lymphoproliferative disease

          8. History or presence of any other form of malignancy

          9. Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic,
             hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic or cerebral
             disease

         10. History of congestive heart failure or unstable angina

         11. History of any autoimmune disease other than RA

         12. Major surgery within 12 weeks and planned major surgery

         13. History of serious infection

         14. Pre-existing central nervous system demyelinating disorders

         15. Administration of live or live-attenuated vaccine within 4 weeks of screening

         16. Clinically significant adverse reaction to murine or chimeric proteins

         17. History or presence of any medical or psychiatric condition or disease, or clinically
             significant laboratory abnormality

         18. Participation in any clinical study of an investigational product within the previous
             3 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>EPIRUS Clinical Development</last_name>
    <email>info@epirusbiopharma.com</email>
  </overall_contact>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

